Please ensure Javascript is enabled for purposes of website accessibility

Why Heron Therapeutics Stock Broke Down in April

By George Budwell - Updated May 7, 2019 at 9:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Heron's falling share price last month turned out to be a bad omen.

What happened

Heron Therapeutics (HRTX 2.59%), a commercial-stage biotech, saw its shares fall by 11.7% over the course of April, according to data from S&P Global Market Intelligence. This double-digit drop is noteworthy because it occurred ahead of the company's official announcement that the Food and Drug Administration (FDA) had issued a Complete Response Letter for the experimental pain medication HTX-011.

According to an 8-K filing with the SEC, the FDA sent Heron its decision regarding HTX-011 on April 30. But the company didn't dole out the bad news to investors until the following day, May 1. The market clearly sniffed out this forthcoming rejection -- even though it came as a surprise to most analysts and industry insiders.

Chalkboard with the word "pain" written on it in capital letters.

Image Source: Getty Images.

So what

Heron is banking on HTX-011 to transform the company into a super-charged growth vehicle in the next decade. The company's first two FDA-approved products -- Sustol and Cinvanti indicated for the management of chemotherapy-induced vomiting and nausea -- simply aren't big earners, after all. HTX-011, by contrast, has a chance at hauling in several hundred million in sales at its peak -- even as a direct competitor to Pacira BioSciences rival pain reliever Exparel.

Now what

In a follow-up conference call, Heron's management stressed that the FDA didn't request any additional clinical studies. Rather, the primary reason for the rejection was missing info on the drug's chemistry, manufacturing and controls -- an issue that pops up fairly often during regulatory reviews.

As such, Heron should be able to make the necessary corrections and get this regulatory filing back to the FDA in a timely fashion. The bad news is that HTX-011 now seems destined to launch next year at the earliest. That's not the end of the world, but Heron's share price will probably stagnate until this regulatory risk factor is off the table.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
HRTX
$3.57 (2.59%) $0.09
Pacira BioSciences, Inc. Stock Quote
Pacira BioSciences, Inc.
PCRX
$63.04 (2.65%) $1.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.